Home » Stocks » ABCL

AbCellera Biologics, Inc. (ABCL)

Stock Price: $49.08 USD 4.67 (10.52%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
After-hours: $49.00 -0.08 (-0.16%) Jan 19, 7:52 PM
Market Cap 13.03B
Revenue (ttm) 28.45M
Net Income (ttm) 277,000
Shares Out 266.32M
EPS (ttm) 0.00
PE Ratio 47,187.94
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $49.08
Previous Close $44.41
Change ($) 4.67
Change (%) 10.52%
Day's Open 44.94
Day's Range 44.94 - 49.32
Day's Volume 1,252,178
52-Week Range 36.59 - 58.90


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 hours ago

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni MouseĀ® technology.

CNBC Television - 6 days ago

AbCellera CEO on effectiveness of Covid-19 anitbody treatment

AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments.

GuruFocus - 4 weeks ago

Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Pi...

Other stocks mentioned: FDMT
Business Wire - 4 weeks ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico

Business Wire - 1 month ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

The Motley Fool - 1 month ago

Hot initial public offerings aren't just for technology companies.

Other stocks mentioned: CERT
Barrons - 1 month ago

Four companies increased the size of their deals.

Other stocks mentioned: CERT
Business Wire - 1 month ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.

InvestorPlace - 1 month ago

AbCellera is continuing forward with its IPO plans and has provided new details in a filing with the SEC that investors will want to know. The post ABCL Stock IPO: When Does AbCellera Go Public?

Seeking Alpha - 1 month ago

AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide.

Market Watch - 1 month ago

AbCellera Biologics Inc. ABCL, said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $...

BioSpace - 1 month ago

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19.

Reuters - 1 month ago

Peter Thiel-backed biotech developer AbCellera Biologics Inc, which has partnered with Eli Lilly for its COVID-19 antibody drug, on Friday filed for an initial public offering on the Nasdaq.

NASDAQ - 1 month ago

AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, filed on Friday with the SEC to raise up to $200 million in an initial public offering.

SEC - 1 month ago

AbCellera Biologics, Inc. has filed to go public with an IPO on the NASDAQ.

About ABCL

AbCellera Biologics develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquarter... [Read more...]

IPO Date
Dec 11, 2020
Carl L. G. Hansen
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for ABCL is 51.40, which is an increase of 4.73% from the latest price.

Price Target
(4.73% upside)